サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1428056

尿素サイクル異常症治療の世界市場レポート 2024

Urea Cycle Disorders Treatment Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
尿素サイクル異常症治療の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

尿素サイクル異常症治療の市場規模は、今後数年間で着実に成長すると予想されています。 2028年には3.9%の年間複合成長率（CAGR）で15億7,000万米ドルに成長すると予想されます。予測期間で予想される成長は、酵素補充療法の進歩、新生児スクリーニングプログラムの拡大、調査活動における協力の強化、治療選択肢の拡大、遠隔医療と遠隔ケアの利用の増加に起因すると考えられます。予測期間中に予想される注目すべき動向には、高度な遺伝子編集技術の導入、意識向上と支持活動に重点を置いた取り組み、再生医療アプローチの探求、長期的な安全性と有効性の研究の実施、個別化された栄養療法の開発などが含まれます。

尿素サイクル異常症の有病率の増加により、尿素サイクル異常症治療市場の成長が促進されると予想されます。尿素サイクル異常症は、肝臓が血液からアンモニアを除去するために不可欠な酵素または輸送体分子の欠陥によって引き起こされる先天性代謝障害です。尿素サイクル異常症の有病率の増加は、主に遺伝的障害に起因します。尿素サイクル異常症（UCD）として特定される症状にはアンモニアの蓄積が関与しており、副作用を管理および軽減するための食事管理、投薬、モニタリングを含むカスタマイズされた治療戦略が必要となります。 StatPearls Publishing LLCによると、2023年 4月の時点で、オルニチントランスカルバミラーゼ欠損に起因する尿素サイクル異常症の有病率は140,000人に1人であると報告されています。さらに、2021年1月、国立医学図書館は、米国における出生35,000人当たり尿素サイクル異常症の新たな症例が113人であると報告しました。したがって、尿素サイクル異常症の有病率の急増は、尿素サイクル異常症治療市場の成長の重要な推進力です。

慢性腎臓病の症例数の増加は、尿素サイクル異常症治療市場の拡大に寄与すると予想されます。時間の経過とともに腎機能が徐々に失われることを特徴とする慢性腎臓病（CKD）は、代謝老廃物、特に腎機能障害による尿素濃度の上昇を管理するために尿素サイクル異常症の治療を利用します。 2023年11月の時点で、推定720万人が慢性腎臓病（CKD）ステージ1～5を患っていると考えられており、英国では約350万人が症状が進行するCKD後期（ステージ3～5）を経験しています。コントロールが難しいです。したがって、慢性腎臓障害の症例数の増加は、尿素サイクル異常症治療市場の成長の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の尿素サイクル異常症治療市場促進要因と制約要因
    • 市場の促進要因
    • 市場の抑制要因
  • 世界の尿素サイクル異常症治療市場規模実績と成長、2018年から2023年
  • 世界の尿素サイクル異常症治療市場規模と成長予測、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の尿素サイクル異常症治療市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • アミノ酸サプリメント
  • フェニル酪酸ナトリウム
  • グリセロールフェニルブチレート
  • 安息香酸ナトリウム
  • その他の治療法
  • 世界の尿素サイクル異常症治療市場、酵素欠乏によるセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • OTC-オルニチントランスカルバミラーゼ
  • AS-アルギニノコハク酸シンテターゼ（シトルリン血症）
  • AG-アルギナーゼ
  • AL-アルギニノコハク酸リアーゼ
  • CPS1-カルバモイルリン酸シンターゼ
  • 世界の尿素サイクル異常症治療市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 注射剤
  • 世界の尿素サイクル異常症治療市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 地域および国の分析

  • 世界の尿素サイクル異常症治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の尿素サイクル異常症治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 尿素サイクル異常症治療市場の競合情勢
  • 尿素サイクル異常症治療市場の企業プロファイル
    • F. Hoffmann-La Roche AG
    • AbbVie Inc.
    • Novartis AG
    • Sanofi SA
    • AstraZeneca Plc.

第31章 その他の大手および革新的な企業

  • Alexion Pharmaceuticals Inc.
  • Abbott Laboratories Inc.
  • GlaxoSmithKline Plc
  • Takeda Pharmaceutical Co. Ltd.
  • Danone SA
  • Merck KGaA
  • Bausch Health Companies Inc.
  • Grifols SA
  • Horizon Therapeutics Plc
  • Leadiant Biosciences Inc.
  • BioMarin Pharmaceutical Inc.
  • Ultragenyx Pharmaceutical Inc.
  • Travere Therapeutics Inc.
  • Arcturus Therapeutics Holdings Inc.
  • Selecta Biosciences Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13900

Urea cycle disorder treatment involves managing rare genetic diseases in which the body lacks the necessary enzymes to break down ammonia, leading to its accumulation and potential toxicity. The primary goal of urea cycle disorder treatment is to reduce blood ammonia levels.

The main types of treatment for urea cycle disorders include amino acid supplements, sodium phenylbutyrate, glycerol phenylbutyrate, sodium benzoate, and others. Amino acid supplements contain one or more of the nine essential amino acids that the body requires but cannot produce independently. Specific types of enzyme deficiencies are addressed, such as OTC (ornithine transcarbamylase), AS (argininosuccinate synthetase) for citrullinemia, AG (arginase), AL (argininosuccinate lyase), and CPS1 (carbamoyl phosphate synthase). These treatments can be administered orally and through injections, and they are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The urea cycle disorders treatment market research report is one of a series of new reports from The Business Research Company that provides urea cycle disorders treatment market statistics, including urea cycle disorders treatment industry global market size, regional shares, competitors with a urea cycle disorders treatment market share, detailed urea cycle disorders treatment market segments, market trends and opportunities, and any further data you may need to thrive in the urea cycle disorders treatment industry. This urea cycle disorders treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The urea cycle disorders treatment market size has grown steadily in recent years. It will grow from $1.29 billion in 2023 to $1.35 billion in 2024 at a compound annual growth rate (CAGR) of 4.5%. The expansion observed in the historical period can be attributed to increased awareness and education, advancements in newborn screening practices, the emergence of patient support networks, and the establishment of standard of care guidelines.

The urea cycle disorders treatment market size is expected to see steady growth in the next few years. It will grow to $1.57 billion in 2028 at a compound annual growth rate (CAGR) of 3.9%. The anticipated growth in the forecast period can be attributed to advancements in enzyme replacement therapy, the expansion of newborn screening programs, heightened collaboration in research efforts, the broadening of therapeutic options, and the increasing utilization of telemedicine and remote care. Noteworthy trends expected during the forecast period include the implementation of advanced gene editing techniques, initiatives focused on awareness and advocacy, the exploration of regenerative medicine approaches, the conduct of long-term safety and efficacy studies, and the development of personalized nutritional therapies.

The increasing prevalence of urea cycle disorders is anticipated to drive the growth of the market for urea cycle disorders treatment. Urea cycle disorders are metabolic inborn disorders caused by defects in enzymes or transporter molecules crucial for the liver to eliminate ammonia from the blood. The rise in the prevalence of urea cycle disorders is primarily attributed to genetic disorders. Conditions identified as urea cycle disorders (UCD) involve the accumulation of ammonia, leading to customized treatment strategies that encompass dietary control, medication, and monitoring to manage and mitigate the adverse effects. As of April 2023, the prevalence of urea cycle disorders resulting from ornithine transcarbamylase deficiency was reported as 1 in 140,000 people according to StatPearls Publishing LLC. Additionally, in January 2021, the National Library of Medicine reported 113 new cases of urea cycle disorders per 35,000 live births in the United States. Therefore, the surge in the prevalence of urea cycle disorders is a significant driver of the urea cycle disorders treatment market's growth.

The increasing number of chronic kidney disorder cases is expected to contribute to the expansion of the urea cycle disorders treatment market. Chronic kidney disease (CKD), characterized by the gradual loss of kidney function over time, utilizes urea cycle disorder treatment to manage metabolic waste, especially elevated urea levels due to impaired kidney function. As of November 2023, an estimated 7.2 million individuals are believed to have chronic kidney disease (CKD) stages 1-5, with approximately 3.5 million people in the UK experiencing the later stages of CKD (stages 3-5), where symptoms become progressively challenging to control. Hence, the growing number of chronic kidney disorder cases is a driving force behind the urea cycle disorders treatment market's growth.

A product innovation has emerged as a notable trend, with major companies focusing on creating innovative products to strengthen their market positions. For example, in September 2022, Medunik USA introduced Pheburane oral pellets, a unique and flavor-masking formulation of sodium phenylbutyrate (NaPB) for the long-term management of certain urea cycle disorders. Pheburane, a prescription drug used in conjunction with a specific diet, offers a convenient administration method without the need for mixing. It can be consumed alone or sprinkled on food, enhancing patient compliance.

Major players in the urea cycle disorder treatment market are adopting a strategic partnership approach to advance therapies and improve disease management. In October 2021, Boehringer Ingelheim collaborated with Thoeris GmbH, an early-stage biopharmaceutical company in Europe, to explore novel therapies for patients with urea cycle disorders (UCDs). UCDs, rare diseases resulting from genetic liver dysfunctions leading to elevated ammonia levels, lack sufficient treatments. Boehringer Ingelheim's expertise in drug discovery and development aims to advance potential medications into clinical trials.

In November 2023, Zevra Therapeutics Inc. acquired Acer Therapeutics Inc. for $91 million, providing Zevra access to rare disease assets, including Edsivo and Olpruva. Edsivo is undergoing Phase III trials for vascular Ehlers-Danlos syndrome, while Olpruva has received FDA approval for certain urea cycle diseases. This acquisition enhances Zevra's market presence and diversifies its revenue stream in the rare disease therapeutics sector. Acer Therapeutics Inc. is a pharmaceutical company offering treatments for urea cycle disorders.

Major companies operating in the urea cycle disorders treatment market report are F. Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca Plc., Alexion Pharmaceuticals Inc., Abbott Laboratories Inc., GlaxoSmithKline PLC, Takeda Pharmaceutical Co. Ltd., Danone S.A., Merck KGaA, Bausch Health Companies Inc., Grifols S.A., Horizon Therapeutics PLC, Leadiant Biosciences Inc., BioMarin Pharmaceutical Inc., Ultragenyx Pharmaceutical Inc., Travere Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Selecta Biosciences Inc., Nutricia North America, Acer Therapeutics Inc., Aeglea BioTherapeutics Inc., Synlogic Inc., Lucane Pharma SA, Recordati Rare Diseases Inc., Orpharma Pty Ltd., Mead Johnson & Company LLC

North America was the largest region in the urea cycle disorders treatment market in 2023. The regions covered in the urea cycle disorders treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the urea cycle disorders treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The urea cycle disorders treatment market includes revenues earned by entities by hemodialysis, dietary management, and genetic counselling. The market value includes the value of related goods sold by the service provider or included within the service offering. The urea cycle disorders treatment market also includes sales of arginine, sodium phenylacetate, sodium benzoate, and carglumic acid. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Urea Cycle Disorders Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on urea cycle disorders treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for urea cycle disorders treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The urea cycle disorders treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Treatment: Amino Acid Supplements; Sodium Phenylbutyrate; Glycerol Phenylbutyrate; Sodium Benzoate; Other Treatments
  • 2) By Enzyme Deficiency: Ornithine Transcarbamylase (OTC); Argininosuccinate Synthetase (AS); Arginase (AG); Argininosuccinate Lyase (AL); Carbamoyl Phosphate Synthase (CPS1)
  • 3) By Route of Administration: Oral; Injectables
  • 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Companies Mentioned: F. Hoffmann-La Roche AG; AbbVie Inc.; Novartis AG; Sanofi S.A.; AstraZeneca Plc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Urea Cycle Disorders Treatment Market Characteristics

3. Urea Cycle Disorders Treatment Market Trends And Strategies

4. Urea Cycle Disorders Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Urea Cycle Disorders Treatment Market Size and Growth

  • 5.1. Global Urea Cycle Disorders Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Urea Cycle Disorders Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Urea Cycle Disorders Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Urea Cycle Disorders Treatment Market Segmentation

  • 6.1. Global Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Amino Acid Supplements
  • Sodium Phenylbutyrate
  • Glycerol Phenylbutyrate
  • Sodium Benzoate
  • Other Treatments
  • 6.2. Global Urea Cycle Disorders Treatment Market, Segmentation By Enzyme Deficiency, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • OTC - Ornithine Transcarbamylase
  • AS - Argininosuccinate Synthetase (citrullinemia)
  • AG - Arginase
  • AL - Argininosuccinate Lyase
  • CPS1 - Carbamoyl Phosphate Synthase
  • 6.3. Global Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Injectables
  • 6.4. Global Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

7. Urea Cycle Disorders Treatment Market Regional And Country Analysis

  • 7.1. Global Urea Cycle Disorders Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Urea Cycle Disorders Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Urea Cycle Disorders Treatment Market

  • 8.1. Asia-Pacific Urea Cycle Disorders Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Urea Cycle Disorders Treatment Market

  • 9.1. China Urea Cycle Disorders Treatment Market Overview
  • 9.2. China Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Urea Cycle Disorders Treatment Market

  • 10.1. India Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Urea Cycle Disorders Treatment Market

  • 11.1. Japan Urea Cycle Disorders Treatment Market Overview
  • 11.2. Japan Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Urea Cycle Disorders Treatment Market

  • 12.1. Australia Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Urea Cycle Disorders Treatment Market

  • 13.1. Indonesia Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Urea Cycle Disorders Treatment Market

  • 14.1. South Korea Urea Cycle Disorders Treatment Market Overview
  • 14.2. South Korea Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Urea Cycle Disorders Treatment Market

  • 15.1. Western Europe Urea Cycle Disorders Treatment Market Overview
  • 15.2. Western Europe Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Urea Cycle Disorders Treatment Market

  • 16.1. UK Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Urea Cycle Disorders Treatment Market

  • 17.1. Germany Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Urea Cycle Disorders Treatment Market

  • 18.1. France Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Urea Cycle Disorders Treatment Market

  • 19.1. Italy Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Urea Cycle Disorders Treatment Market

  • 20.1. Spain Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Urea Cycle Disorders Treatment Market

  • 21.1. Eastern Europe Urea Cycle Disorders Treatment Market Overview
  • 21.2. Eastern Europe Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Urea Cycle Disorders Treatment Market

  • 22.1. Russia Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Urea Cycle Disorders Treatment Market

  • 23.1. North America Urea Cycle Disorders Treatment Market Overview
  • 23.2. North America Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Urea Cycle Disorders Treatment Market

  • 24.1. USA Urea Cycle Disorders Treatment Market Overview
  • 24.2. USA Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Urea Cycle Disorders Treatment Market

  • 25.1. Canada Urea Cycle Disorders Treatment Market Overview
  • 25.2. Canada Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Urea Cycle Disorders Treatment Market

  • 26.1. South America Urea Cycle Disorders Treatment Market Overview
  • 26.2. South America Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Urea Cycle Disorders Treatment Market

  • 27.1. Brazil Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Urea Cycle Disorders Treatment Market

  • 28.1. Middle East Urea Cycle Disorders Treatment Market Overview
  • 28.2. Middle East Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Urea Cycle Disorders Treatment Market

  • 29.1. Africa Urea Cycle Disorders Treatment Market Overview
  • 29.2. Africa Urea Cycle Disorders Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Urea Cycle Disorders Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Urea Cycle Disorders Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Urea Cycle Disorders Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Urea Cycle Disorders Treatment Market Competitive Landscape
  • 30.2. Urea Cycle Disorders Treatment Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche AG
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. AbbVie Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Novartis AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Sanofi S.A.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. AstraZeneca Plc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Urea Cycle Disorders Treatment Market Other Major And Innovative Companies

  • 31.1. Alexion Pharmaceuticals Inc.
  • 31.2. Abbott Laboratories Inc.
  • 31.3. GlaxoSmithKline Plc
  • 31.4. Takeda Pharmaceutical Co. Ltd.
  • 31.5. Danone S.A.
  • 31.6. Merck KGaA
  • 31.7. Bausch Health Companies Inc.
  • 31.8. Grifols S.A.
  • 31.9. Horizon Therapeutics Plc
  • 31.10. Leadiant Biosciences Inc.
  • 31.11. BioMarin Pharmaceutical Inc.
  • 31.12. Ultragenyx Pharmaceutical Inc.
  • 31.13. Travere Therapeutics Inc.
  • 31.14. Arcturus Therapeutics Holdings Inc.
  • 31.15. Selecta Biosciences Inc.

32. Global Urea Cycle Disorders Treatment Market Competitive Benchmarking

33. Global Urea Cycle Disorders Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Urea Cycle Disorders Treatment Market

35. Urea Cycle Disorders Treatment Market Future Outlook and Potential Analysis

  • 35.1 Urea Cycle Disorders Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Urea Cycle Disorders Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Urea Cycle Disorders Treatment Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer